Reviewing ChemoCentryx (CCXI) and MediWound (MDWD)

ChemoCentryx (NASDAQ: CCXI) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Volatility and Risk

ChemoCentryx has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.

Valuation and Earnings

This table compares ChemoCentryx and MediWound’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ChemoCentryx $26.31 million 14.15 -$30.76 million ($0.62) -12.47
MediWound $2.17 million 50.08 -$16.18 million ($0.75) -6.60

MediWound has higher revenue, but lower earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.


This table compares ChemoCentryx and MediWound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A -62.62% -20.58%
MediWound -752.78% -326.32% -48.65%

Analyst Ratings

This is a breakdown of current ratings for ChemoCentryx and MediWound, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 1 0 2.50
MediWound 0 0 5 0 3.00

MediWound has a consensus price target of $10.00, suggesting a potential upside of 102.02%. Given MediWound’s stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than ChemoCentryx.

Institutional & Insider Ownership

50.1% of ChemoCentryx shares are held by institutional investors. Comparatively, 19.6% of MediWound shares are held by institutional investors. 26.8% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


ChemoCentryx beats MediWound on 8 of the 13 factors compared between the two stocks.

ChemoCentryx Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply